Compare Novartis AG (NVS) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Schwab US Dividend Equity ETF — how do they compare? Novartis AG trades at $142.04 (market cap $274.00B), while Schwab US Dividend Equity ETF trades at $33.12 (market cap $108.68B). The key difference: Novartis AG is far larger — about 2.5× Schwab US Dividend Equity ETF's market cap, and Novartis AG pays a 3.31% dividend while Schwab US Dividend Equity ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Schwab US Dividend Equity ETF for 62 Days on average.
| NVS | SCHD | |
|---|---|---|
Market Cap | $274.00B | $108.68B |
Volume | 1,852,137 | 21,463,071 |
Sector | Health | Broad Market / Factor |
52-Week High | $168.62 | $35.21 |
52-Week Low | $121.80 | $26.44 |
Typical Hold Time | 82 Days | 62 Days |
Enterprise Value | $315.32B | — |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
SCHD trades at $32.65, down 0.61% on the day, with a bearish technical signal driven by moving averages. The ETF has outperformed the S&P 500 in 2026, with dividend growth attracting income investors. Recent news highlights its defensive tilt and quality focus amid a market pullback.
Outlook is mixed: strong dividend appeal and low fees support long-term income, but technical weakness and interest rate sensitivity pose near-term risks. Investors should weigh SCHD's consistent payout growth against potential underperformance in rising rate environments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
